Do Not Use Cycloxigenase-2 Inhibitors in STEMI.
نویسنده
چکیده
To the Editor: It is quite encouraging to read the TSOC Guideline article “2012 Guidelines of the Taiwan Society of Cardiology for the Management of ST-Segment Elevation Myocardial Infarction” by Li et al. 1 Though I wholeheartedly agree with and appreciate this guideline, I find it necessary to take issue with a comment about nonsteroidal anti-inflammatory drugs (NSAIDs) because the reader may be confused from the statement “NSAIDs, except aspirin, and cycloxygenase-2 (COX-2) inhibitors, should not be used at the acute stage of STEMI”. NSAIDs contain diverse groups of drugs with analgesic, antipyretic, and anti-inflammatory effects. Most NSAIDs function as a nonselective inhibitor of the enzyme cyclo-oxygenase (COX) to block the formation of prostaglandins and thromboxane, enabling the body to ease off its inflammatory reaction. Gastrointestinal irritation is one of the main adverse drug reactions (ADRs) of NSAIDs. The discovery of selective COX-2 inhibitors brought attention to the NSAIDs with decreased gastrointestinal ADRs. However, selective COX-2 inhibitors were later found to increase the risks of re-infarction, stroke and vascular death. 2 Immediate discontinuation of COX-2 inhibitors and other NSAIDs except for aspirin at the time of STEMI was thereafter recommended. 3 The latest emergency cardiac care guideline re-emphasized that NSAIDs other than aspirin, both nonselective and COX-2 selective, should not be administered during hospitalization for STEMI because of the increased risk of mortality, reinfarction, hypertension, heart failure, and myocardial rupture associated with their use (Class III, LOE C). 4 For genetic and lifestyle differences, it should be the era to have our own guidelines.
منابع مشابه
[A short history of anti-rheumatic therapy. III. Non steroidal anti-inflammatory drugs].
The chemical advances of the 20th century led to the synthesis of non steroidal anti-inflammatory drugs (NSAIDs), beginning from phenylbutazone and indomethacin and continuing with other new drugs, including ibuprofen, diclofenac, naproxen, piroxicam and, more recently, the highly selective COX-2 inhibitors (coxibs). This progress derived from the discovery of the mechanism of action of these d...
متن کاملThe efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
OBJECTIVE We reviewed the literature and performed a meta-analysis comparing the safety and efficacy of adjunctive use of reduced-dose thrombolytics and glycoprotein (Gp) IIbIIIa inhibitors to the sole use of Gp IIbIIIa inhibitors before percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI). BACKGROUND Early reperfusion i...
متن کاملAromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Orally active aromatase inhibitors (AIs) have gained attention for treatment of infertile women with endometriosis in whom aromatase p450 is aberrantly expressed. This review aimed to critically appraise and summarize the available evidence concerning the use of AIs for management of endometriosis-associated infertility. PubMed was searched to May 2015 with the following key words: endometriosi...
متن کاملUpstream vs deferred administration of small-molecule glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: insights from randomized clinical trials.
BACKGROUND Recent data have demonstrated similar outcomes for patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) and are treated with small-molecule glycoprotein IIb/IIIa inhibitors (smGPIs) compared with those treated with abciximab. In the present study, a meta-analysis was performed to evaluate the relative safety and...
متن کاملDevelopment of systems of care for ST-elevation myocardial infarction patients: current state of ST-elevation myocardial infarction care.
Advances in the treatment of ST-elevation myocardial infarction (STEMI) over the past 20 years have resulted in dramatic reductions in death attributable to STEMI. In large part, this reduction has been due to early reperfusion and advances in medical therapy.1 The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and the European Society of Cardiology guidelines ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Acta Cardiologica Sinica
دوره 29 2 شماره
صفحات -
تاریخ انتشار 2013